FDA Approves Second Interchangeable Insulin Product, Rezvoglar (insulin glargine-aglr)

November 18, 2022 --  The U.S. Food and Drug Administration approves the second interchangeable biosimilar insulin product to Lantus (insulin glargine), Eli Lilly’s Rezvoglar (insulin glargine-aglr).
Rezvoglar is a long-acting human...